Patient-reported cognition at the end of a PCSK9 antibody trial

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

CETP inhibition: Lessons from two decades of clinical trials
CETP inhibition: Lessons from two decades of clinical trials
MinuteCE®
CETP inhibition: Lessons from two decades of clinical trials
0.50 program credits
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
0.50 program credits
Understanding the role of triglycerides in the assessment of residual risk
Understanding the role of triglycerides in the assessment of residual risk
MinuteCE®
Understanding the role of triglycerides in the assessment of residual risk
0.50 program credits
- Prof. Alberto Zambon MD, PhD, FAHA
0.50 program credits
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
MinuteCE®
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
0.50 program credits
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
0.50 program credits
The current state of secondary prevention in high-risk patients
The current state of secondary prevention in high-risk patients
Hyperlipidemia
The current state of secondary prevention in high-risk patients
- Prof. Thomas Lüscher, MD